Intrinsic value of USANA Health Sciences - USNA

Previous Close

$119.64

  Intrinsic Value

$129.80

stock screener

  Rating & Target

hold

+8%

Previous close

$119.64

 
Intrinsic value

$129.80

 
Up/down potential

+8%

 
Rating

hold

We calculate the intrinsic value of USNA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  17.30
  16.07
  14.96
  13.97
  13.07
  12.26
  11.54
  10.88
  10.29
  9.77
  9.29
  8.86
  8.47
  8.13
  7.81
  7.53
  7.28
  7.05
  6.85
  6.66
  6.50
  6.35
  6.21
  6.09
  5.98
  5.88
  5.79
  5.72
  5.64
  5.58
Revenue, $m
  1,228
  1,426
  1,639
  1,868
  2,112
  2,371
  2,645
  2,933
  3,235
  3,551
  3,880
  4,224
  4,582
  4,954
  5,342
  5,744
  6,162
  6,597
  7,048
  7,518
  8,006
  8,514
  9,043
  9,594
  10,167
  10,766
  11,389
  12,040
  12,720
  13,430
Variable operating expenses, $m
  1,058
  1,227
  1,410
  1,606
  1,815
  2,037
  2,272
  2,519
  2,777
  3,048
  3,325
  3,620
  3,927
  4,246
  4,578
  4,922
  5,281
  5,653
  6,040
  6,443
  6,861
  7,296
  7,750
  8,222
  8,713
  9,226
  9,761
  10,318
  10,901
  11,509
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  1,058
  1,227
  1,410
  1,606
  1,815
  2,037
  2,272
  2,519
  2,777
  3,048
  3,325
  3,620
  3,927
  4,246
  4,578
  4,922
  5,281
  5,653
  6,040
  6,443
  6,861
  7,296
  7,750
  8,222
  8,713
  9,226
  9,761
  10,318
  10,901
  11,509
Operating income, $m
  170
  199
  229
  262
  297
  334
  373
  414
  457
  503
  555
  604
  655
  709
  764
  822
  881
  943
  1,008
  1,075
  1,145
  1,218
  1,293
  1,372
  1,454
  1,540
  1,629
  1,722
  1,819
  1,921
EBITDA, $m
  191
  222
  255
  291
  329
  369
  412
  457
  504
  553
  604
  658
  714
  772
  832
  894
  960
  1,027
  1,098
  1,171
  1,247
  1,326
  1,408
  1,494
  1,583
  1,677
  1,774
  1,875
  1,981
  2,091
Interest expense (income), $m
  0
  0
  1
  3
  5
  7
  9
  11
  13
  15
  18
  20
  23
  26
  28
  31
  35
  38
  41
  45
  48
  52
  56
  60
  64
  69
  74
  78
  83
  89
  94
Earnings before tax, $m
  170
  197
  226
  257
  290
  325
  362
  401
  442
  485
  535
  581
  630
  680
  732
  787
  843
  902
  963
  1,027
  1,093
  1,162
  1,233
  1,308
  1,385
  1,466
  1,551
  1,639
  1,731
  1,827
Tax expense, $m
  46
  53
  61
  69
  78
  88
  98
  108
  119
  131
  144
  157
  170
  184
  198
  212
  228
  244
  260
  277
  295
  314
  333
  353
  374
  396
  419
  442
  467
  493
Net income, $m
  124
  144
  165
  188
  212
  237
  265
  293
  323
  354
  390
  424
  460
  496
  535
  574
  616
  659
  703
  750
  798
  848
  900
  955
  1,011
  1,070
  1,132
  1,196
  1,263
  1,333

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  485
  563
  647
  738
  834
  936
  1,044
  1,158
  1,277
  1,402
  1,532
  1,668
  1,809
  1,956
  2,109
  2,268
  2,433
  2,604
  2,783
  2,968
  3,161
  3,361
  3,570
  3,787
  4,014
  4,250
  4,496
  4,753
  5,022
  5,302
Adjusted assets (=assets-cash), $m
  485
  563
  647
  738
  834
  936
  1,044
  1,158
  1,277
  1,402
  1,532
  1,668
  1,809
  1,956
  2,109
  2,268
  2,433
  2,604
  2,783
  2,968
  3,161
  3,361
  3,570
  3,787
  4,014
  4,250
  4,496
  4,753
  5,022
  5,302
Revenue / Adjusted assets
  2.532
  2.533
  2.533
  2.531
  2.532
  2.533
  2.534
  2.533
  2.533
  2.533
  2.533
  2.532
  2.533
  2.533
  2.533
  2.533
  2.533
  2.533
  2.533
  2.533
  2.533
  2.533
  2.533
  2.533
  2.533
  2.533
  2.533
  2.533
  2.533
  2.533
Average production assets, $m
  150
  174
  200
  228
  258
  289
  323
  358
  395
  433
  473
  515
  559
  604
  652
  701
  752
  805
  860
  917
  977
  1,039
  1,103
  1,170
  1,240
  1,313
  1,390
  1,469
  1,552
  1,638
Working capital, $m
  -57
  -66
  -75
  -86
  -97
  -109
  -122
  -135
  -149
  -163
  -178
  -194
  -211
  -228
  -246
  -264
  -283
  -303
  -324
  -346
  -368
  -392
  -416
  -441
  -468
  -495
  -524
  -554
  -585
  -618
Total debt, $m
  27
  57
  89
  123
  159
  198
  239
  282
  327
  374
  423
  474
  528
  583
  641
  701
  764
  828
  896
  966
  1,039
  1,114
  1,193
  1,276
  1,361
  1,450
  1,544
  1,641
  1,742
  1,848
Total liabilities, $m
  183
  213
  245
  279
  315
  354
  395
  438
  483
  530
  579
  630
  684
  739
  797
  857
  920
  984
  1,052
  1,122
  1,195
  1,271
  1,349
  1,432
  1,517
  1,607
  1,700
  1,797
  1,898
  2,004
Total equity, $m
  302
  350
  403
  459
  519
  582
  649
  720
  794
  872
  953
  1,037
  1,125
  1,217
  1,312
  1,410
  1,513
  1,620
  1,731
  1,846
  1,966
  2,091
  2,221
  2,356
  2,497
  2,644
  2,797
  2,957
  3,123
  3,298
Total liabilities and equity, $m
  485
  563
  648
  738
  834
  936
  1,044
  1,158
  1,277
  1,402
  1,532
  1,667
  1,809
  1,956
  2,109
  2,267
  2,433
  2,604
  2,783
  2,968
  3,161
  3,362
  3,570
  3,788
  4,014
  4,251
  4,497
  4,754
  5,021
  5,302
Debt-to-equity ratio
  0.090
  0.160
  0.220
  0.270
  0.310
  0.340
  0.370
  0.390
  0.410
  0.430
  0.440
  0.460
  0.470
  0.480
  0.490
  0.500
  0.500
  0.510
  0.520
  0.520
  0.530
  0.530
  0.540
  0.540
  0.550
  0.550
  0.550
  0.550
  0.560
  0.560
Adjusted equity ratio
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622
  0.622

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  124
  144
  165
  188
  212
  237
  265
  293
  323
  354
  390
  424
  460
  496
  535
  574
  616
  659
  703
  750
  798
  848
  900
  955
  1,011
  1,070
  1,132
  1,196
  1,263
  1,333
Depreciation, amort., depletion, $m
  21
  23
  26
  29
  32
  35
  39
  43
  46
  50
  49
  54
  58
  63
  68
  73
  78
  84
  90
  96
  102
  108
  115
  122
  129
  137
  145
  153
  162
  171
Funds from operations, $m
  145
  167
  191
  217
  244
  273
  303
  335
  369
  404
  440
  478
  518
  559
  603
  647
  694
  742
  793
  845
  900
  956
  1,015
  1,076
  1,140
  1,207
  1,277
  1,349
  1,425
  1,504
Change in working capital, $m
  -8
  -9
  -10
  -11
  -11
  -12
  -13
  -13
  -14
  -15
  -15
  -16
  -16
  -17
  -18
  -19
  -19
  -20
  -21
  -22
  -22
  -23
  -24
  -25
  -26
  -28
  -29
  -30
  -31
  -33
Cash from operations, $m
  154
  176
  201
  227
  255
  285
  316
  349
  383
  419
  455
  494
  534
  577
  620
  666
  713
  762
  814
  867
  922
  980
  1,039
  1,102
  1,167
  1,235
  1,305
  1,379
  1,456
  1,537
Maintenance CAPEX, $m
  -13
  -16
  -18
  -21
  -24
  -27
  -30
  -34
  -37
  -41
  -45
  -49
  -54
  -58
  -63
  -68
  -73
  -78
  -84
  -90
  -96
  -102
  -108
  -115
  -122
  -129
  -137
  -145
  -153
  -162
New CAPEX, $m
  -22
  -24
  -26
  -28
  -30
  -32
  -33
  -35
  -37
  -39
  -40
  -42
  -44
  -45
  -47
  -49
  -51
  -53
  -55
  -57
  -60
  -62
  -65
  -67
  -70
  -73
  -76
  -79
  -83
  -87
Cash from investing activities, $m
  -35
  -40
  -44
  -49
  -54
  -59
  -63
  -69
  -74
  -80
  -85
  -91
  -98
  -103
  -110
  -117
  -124
  -131
  -139
  -147
  -156
  -164
  -173
  -182
  -192
  -202
  -213
  -224
  -236
  -249
Free cash flow, $m
  118
  137
  157
  178
  202
  226
  252
  280
  309
  339
  370
  403
  437
  473
  510
  549
  589
  631
  675
  720
  767
  816
  867
  920
  975
  1,032
  1,092
  1,155
  1,220
  1,289
Issuance/(repayment) of debt, $m
  27
  29
  32
  34
  36
  39
  41
  43
  45
  47
  49
  51
  53
  56
  58
  60
  62
  65
  67
  70
  73
  76
  79
  82
  86
  89
  93
  97
  101
  106
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  27
  29
  32
  34
  36
  39
  41
  43
  45
  47
  49
  51
  53
  56
  58
  60
  62
  65
  67
  70
  73
  76
  79
  82
  86
  89
  93
  97
  101
  106
Total cash flow (excl. dividends), $m
  146
  166
  189
  213
  238
  265
  293
  323
  354
  386
  419
  454
  490
  528
  568
  609
  652
  696
  742
  790
  840
  892
  946
  1,002
  1,061
  1,122
  1,186
  1,252
  1,322
  1,394
Retained Cash Flow (-), $m
  -44
  -48
  -52
  -56
  -60
  -64
  -67
  -71
  -74
  -78
  -81
  -84
  -88
  -91
  -95
  -99
  -103
  -107
  -111
  -115
  -120
  -125
  -130
  -135
  -141
  -147
  -153
  -160
  -167
  -174
Prev. year cash balance distribution, $m
  106
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  207
  118
  136
  156
  178
  201
  226
  252
  280
  309
  338
  369
  403
  437
  473
  510
  549
  589
  631
  675
  720
  767
  816
  867
  920
  975
  1,032
  1,092
  1,155
  1,220
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  199
  108
  119
  129
  138
  146
  153
  158
  161
  162
  160
  158
  153
  147
  139
  130
  119
  109
  97
  86
  74
  64
  53
  44
  36
  28
  22
  17
  13
  9
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia. Its product lines include USANA Nutritionals Essentials, Optimizers, Foods, Sense-beautiful science and All Other. Its USANA Nutritionals Essentials product line includes vitamin and mineral supplements that provide a foundation of total body nutrition for every age group beginning with children of approximately one year. Its Optimizers product line consists of targeted supplements designed to meet individual health and nutritional needs. Its Sense-beautiful science product line includes science-based, personal care products that support skin and hair by providing topical nourishment, moisturization and protection.

FINANCIAL RATIOS  of  USANA Health Sciences (USNA)

Valuation Ratios
P/E Ratio 29.3
Price to Sales 2.9
Price to Book 9
Price to Tangible Book
Price to Cash Flow 21.4
Price to Free Cash Flow 28.2
Growth Rates
Sales Growth Rate 9.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 37.5%
Cap. Spend. - 3 Yr. Gr. Rate 32.8%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 22.4%
Ret/ On Assets - 3 Yr. Avg. 22.8%
Return On Total Capital 33%
Ret/ On T. Cap. - 3 Yr. Avg. 33.8%
Return On Equity 33%
Return On Equity - 3 Yr. Avg. 33.8%
Asset Turnover 2.3
Profitability Ratios
Gross Margin 82.1%
Gross Margin - 3 Yr. Avg. 82.3%
EBITDA Margin 15.1%
EBITDA Margin - 3 Yr. Avg. 15.9%
Operating Margin 13.8%
Oper. Margin - 3 Yr. Avg. 14.7%
Pre-Tax Margin 13.8%
Pre-Tax Margin - 3 Yr. Avg. 14.7%
Net Profit Margin 9.9%
Net Profit Margin - 3 Yr. Avg. 10%
Effective Tax Rate 28.1%
Eff/ Tax Rate - 3 Yr. Avg. 31.7%
Payout Ratio 0%

USNA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the USNA stock intrinsic value calculation we used $1047.265 million for the last fiscal year's total revenue generated by USANA Health Sciences. The default revenue input number comes from 0001 income statement of USANA Health Sciences. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our USNA stock valuation model: a) initial revenue growth rate of 17.3% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for USNA is calculated based on our internal credit rating of USANA Health Sciences, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of USANA Health Sciences.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of USNA stock the variable cost ratio is equal to 86.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for USNA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for USANA Health Sciences.

Corporate tax rate of 27% is the nominal tax rate for USANA Health Sciences. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the USNA stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for USNA are equal to 12.2%.

Life of production assets of 9.6 years is the average useful life of capital assets used in USANA Health Sciences operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for USNA is equal to -4.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $363.21 million for USANA Health Sciences - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 24.255 million for USANA Health Sciences is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of USANA Health Sciences at the current share price and the inputted number of shares is $2.9 billion.

RELATED COMPANIES Price Int.Val. Rating
RELV Reliv Internat 4.76 1.65  str.sell
NHTC Natural Health 22.76 49.70  str.buy
LFVN Lifevantage 12.05 16.88  buy
MTEX Mannatech 17.14 10.50  sell
NUS Nu Skin Enterp 66.57 874.53  str.buy
NATR Nature's S 9.04 1.56  str.sell
AVP Avon Products 2.03 0.44  str.sell
MED Medifast 156.47 2,363.52  str.buy
HLF Herbalife Nutr 54.72 27.58  str.sell

COMPANY NEWS

▶ 3 Small Growth Stocks Flying Under the Radar   [Jul-31-18 10:18AM  Investopedia]
▶ USANA Health: 2Q Earnings Snapshot   [Jul-24-18 05:39PM  Associated Press]
▶ These 5 Top Stocks Are Near Buy Points From This Bullish Base   [Jul-05-18 04:03PM  Investor's Business Daily]
▶ Is It Time To Buy USANA Health Sciences Inc (NYSE:USNA)?   [Jun-22-18 11:48AM  Simply Wall St.]
▶ USANA Manufacturing Facility Passes Rigorous Audit   [May-07-18 08:31AM  PR Newswire]
▶ At $96.05, Is USANA Health Sciences Inc (NYSE:USNA) A Buy?   [Apr-25-18 02:18PM  Simply Wall St.]
▶ USANA Health: 1Q Earnings Snapshot   [Apr-24-18 05:24PM  Associated Press]
▶ Best-In-Class Growth Stocks   [Feb-09-18 11:02AM  Simply Wall St.]
▶ USANA Health reports 4Q loss   [Feb-06-18 06:45PM  Associated Press]
▶ Top 10 Direct Sales Companies in USA   [Nov-02-17 09:45AM  Insider Monkey]
▶ USANA Health posts 3Q profit   [Oct-24-17 05:43PM  Associated Press]
▶ USANA Launches Two New Products in Canada   [Oct-14-17 03:00PM  CNW Group]
▶ USANA Stands Committed to Ethical Business Practices   [Sep-12-17 08:30AM  PR Newswire]
▶ You Are What You Eat (And Drink)   [Sep-07-17 08:07AM  PR Newswire]
▶ USANA Announces New Skincare Line   [Aug-23-17 08:07AM  PR Newswire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.